Pimavanserin is an atypical antipsychotic entering Phase III trials in December 2009. The second stage of trials focused on the drug's safety and effectiveness in schizophrenia, and the manufacturer, Biovail Corporation, announced in October 2009 tha...
↧
Pimavanserin in the Treatment of Schizophrenia
↧